From Discovery to Delivery: What the FDA Drug Review Process Means for Rare Disease Patients and Providers

Healthcare & Life Sciences attorney Sara Klock will speak during a bipartisan congressional briefing hosted by the United Mitochondrial Disease Foundation (UMDF) in coordination with the Congressional Mitochondrial Disease Caucus as part of Rare Disease Week. She will examine how the U.S. Food and Drug Administration's (FDA) drug review process affects patients and providers confronting ultra-rare, serious diseases. Using pyruvate dehydrogenase complex deficiency (PDCD) as a case study, Ms. Klock will highlight both progress and persistent challenges involved in developing treatments for life-threatening pediatric mitochondrial diseases. She will share her experience on the legal and regulatory side to complement perspectives from congressional leaders, clinicians and caregivers.

To register, contact sarah.crossan@hklaw.com.